Stock Traders Purchase High Volume of uniQure Call Options (NASDAQ:QURE)

uniQure N.V. (NASDAQ:QURE) was the target of some unusual options trading on Thursday. Traders acquired 24,345 call options on the stock. This is an increase of 181% compared to the average volume of 8,674 call options.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Wolfe Research initiated coverage of uniQure with a “peer perform” rating — an analyst view that is not a clear bullish catalyst and may be seen as neutral to slightly negative given the company’s recent volatility. Wolfe Research story
• Neutral Sentiment: Analyst roundup coverage (5 analysts assessed uniQure) provides additional research flow but no clear consensus upgrade that would offset recent legal and regulatory pressure. Analyst summary
• Negative Sentiment: A securities‑fraud class action has been filed covering purchases between Sept. 24, 2025 and Oct. 31, 2025; multiple national plaintiff firms (including Berger Montague, Kessler Topaz, Pomerantz, Rosen, Levi & Korsinsky, Faruqi & Faruqi, Bragar Eagel & Squire and others) are soliciting lead‑plaintiff applications with an April 13, 2026 deadline — increasing legal risk, potential discovery/costs, and short‑term selling pressure. Berger Montague filing
• Negative Sentiment: Coverage and alerts from many plaintiff firms and services (ClaimsFiler, Bernstein Liebhard, Kahn Swick & Foti, etc.) amplify the publicity around the suit and the April 13 lead‑plaintiff deadline — typically a near‑term headwind for stocks as institutional and retail holders react. Bernstein Liebhard alert
• Negative Sentiment: Media reporting ties the class action to an FDA approval delay and an earlier ~49% stock drop — an allegation that, if litigated, can raise uncertainty about management disclosures and regulatory timing. GazetteXtra report

uniQure Price Performance

QURE stock traded down $7.34 during mid-day trading on Thursday, hitting $17.54. The company had a trading volume of 10,335,743 shares, compared to its average volume of 2,138,183. The company has a 50-day moving average price of $23.76 and a 200 day moving average price of $29.67. uniQure has a 12-month low of $7.76 and a 12-month high of $71.50. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -4.00 and a beta of 0.66. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23.

Analysts Set New Price Targets

QURE has been the subject of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of uniQure in a research report on Wednesday, January 14th. Benchmark reaffirmed a “buy” rating on shares of uniQure in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Finally, Barclays initiated coverage on uniQure in a report on Tuesday, January 27th. They set an “equal weight” rating and a $31.00 price target on the stock. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $58.33.

Insider Activity at uniQure

In other news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the sale, the director directly owned 20,439 shares of the company’s stock, valued at $557,575.92. This represents a 23.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director owned 32,342 shares in the company, valued at approximately $796,260.04. This trade represents a 44.19% decrease in their position. The SEC filing for this sale provides additional information. 4.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of QURE. Jefferies Financial Group Inc. purchased a new stake in uniQure during the second quarter valued at approximately $29,217,000. State Street Corp lifted its holdings in shares of uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. grew its stake in uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after buying an additional 1,785,275 shares during the last quarter. Avoro Capital Advisors LLC grew its stake in uniQure by 38.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after buying an additional 1,705,556 shares during the last quarter. Finally, MPM Bioimpact LLC acquired a new position in uniQure during the 4th quarter valued at about $33,062,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.